DHI

DR Horton
D

DHI

Arincen52/100B

DR Horton return on equity (ROE)

DR Horton's return on equity is 12.71%: net income of 2.94B USD over the last twelve months on shareholders' equity of 23.11B USD.

Today
12.71%
Average, 5 years
20.98%
Low, 5 years
12.71%
High, 5 years
30.96%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 2.94B ÷ 23.11B = 12.71%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is DR Horton's return on equity so high?

Net margin
8.7%
profit on each dollar of sales
Asset turnover
0.95×
sales on each dollar of assets
Equity multiplier
1.51×
assets on each dollar of equity
Return on equity
12.5%
FY2026
  • FY20268.7% × 0.95 × 1.51 = 12.5%
  • FY202510.5% × 0.97 × 1.47 = 14.8%
  • FY202412.9% × 1.02 × 1.43 = 18.8%
  • FY202313.4% × 1.09 × 1.44 = 20.9%
  • FY202217.5% × 1.10 × 1.56 = 30.2%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today12.71%2.94B23.11B
FY202630 Sept 202612.71%2.94B23.11B
FY202530 Sept 202514.82%3.59B24.19B
FY202430 Sept 202418.79%4.76B25.31B
FY202330 Sept 202321.13%4.80B22.70B
FY202230 Sept 202230.40%5.90B19.40B
FY202130 Sept 202128.15%4.19B14.89B
FY202030 Sept 202020.11%2.38B11.84B
FY201930 Sept 201916.15%1.62B10.02B
FY201830 Sept 201816.28%1.46B8.98B
FY201730 Sept 201713.40%1.04B7.75B
FY201630 Sept 201613.05%886.30M6.79B
FY201530 Sept 201512.74%750.70M5.89B
FY201430 Sept 201410.43%533.50M5.12B
FY201330 Sept 201311.40%462.70M4.06B
FY201230 Sept 201226.62%956.30M3.59B
FY201130 Sept 20112.74%71.80M2.62B
FY201030 Sept 20109.38%245.10M2.61B
FY200930 Sept 2009-24.13%-545.30M2.26B
FY200830 Sept 2008-92.92%-2.63B2.83B
FY200730 Sept 2007-12.75%-712.50M5.59B
FY200630 Sept 200619.11%1.23B6.45B
FY200530 Sept 200527.43%1.47B5.36B
FY200430 Sept 200424.62%975.10M3.96B
FY200330 Sept 200320.65%625.96M3.03B
FY200230 Sept 200217.83%404.69M2.27B
FY200130 Sept 200120.56%257.01M1.25B
FY200030 Sept 200019.77%191.72M969.56M
FY199930 Sept 199920.04%159.80M797.60M
FY199830 Sept 199817.00%93.40M549.40M
FY199730 Sept 19978.46%36.20M427.90M
FY199630 Sept 199615.43%27.40M177.60M
FY199530 Sept 199519.32%20.50M106.10M
FY199430 Sept 199420.92%17.70M84.60M
FY199330 Sept 199313.51%8.90M65.90M
FY199230 Sept 199211.09%5.80M52.30M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about DR Horton's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.